0000000000395627

AUTHOR

Bruce A.j. Ponder

showing 2 related works from this author

Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers

2012

Introduction: Cis-acting regulatory single nucleotide polymorphisms (SNPs) at specific loci may modulate penetrance of germline mutations at the same loci by introducing different levels of expression of the wild-type allele. We have previously reported that BRCA2 shows differential allelic expression and we hypothesize that the known variable penetrance of BRCA2 mutations might be associated with this mechanism. Methods: We combined haplotype analysis and differential allelic expression of BRCA2 in breast tissue to identify expression haplotypes and candidate cis-regulatory variants. These candidate variants underwent selection based on in silico predictions for regulatory potential and di…

HeterozygoteColorectal-cancerPredisposition[SDV.CAN]Life Sciences [q-bio]/CancerSingle-nucleotide polymorphismRegulatory Sequences Nucleic AcidBiologyPolymorphism Single NucleotideAssociation03 medical and health sciences0302 clinical medicineBreast cancerGermline mutation[SDV.CAN] Life Sciences [q-bio]/CancerReference ValuesmedicineHumansGenetic Predisposition to DiseaseAllelic imbalanceGene-expressionAllelePromoter Regions Geneticskin and connective tissue diseases030304 developmental biologyMedicine(all)BRCA2 ProteinGenetics0303 health sciencesHuman genomeCarcinomaHaplotypemedicine.diseasePenetranceCommon3. Good healthGene Expression Regulation NeoplasticMinor allele frequencyGene Expression RegulationHaplotypesRegulatory sequence030220 oncology & carcinogenesisBeadarrayCancer researchFemaleCell-lineTranscription FactorsResearch ArticleBreast Cancer Research
researchProduct

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

1994

We have analysed 118 families with inherited medullary thyroid carcinoma (MTC) for mutations of the RET proto-oncogene. These included cases of multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B) and familial MTC (FMTC). Mutations at one of 5 cysteines in the extracellular domain were found in 97% of patients with MEN 2A and 86% with FMTC but not in MEN 2B patients or normal controls. 84% of the MEN2A mutations affected codon 634. MEN 2A patients with a Cys634 to Arg substitution had a greater risk of developing parathyroid disease than those with other codon 634 mutations. Our data show a strong correlation between disease phenotype and the nature and position of the RET mutatio…

medicine.medical_specialtyendocrine system diseasesOncogene RETDNA Mutational AnalysisMolecular Sequence DataMultiple endocrine neoplasia type 2RET proto-oncogeneBiologymedicine.disease_causeProto-Oncogene MasInternal medicineProto-Oncogene ProteinsProto-OncogenesGeneticsmedicineDrosophila ProteinsHumansPoint MutationThyroid NeoplasmsMultiple endocrine neoplasiaDNA PrimersMutationBase SequencePoint mutationMultiple Endocrine NeoplasiaProto-Oncogene Proteins c-retReceptor Protein-Tyrosine KinasesExonsmedicine.diseasePhenotypeEndocrinologyPhenotypeProto-Oncogene Proteins c-retCarcinoma MedullaryCancer researchNature genetics
researchProduct